Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sometimes even good ideas have an expiration date.
The reality is that AXIM stock price has lost 50% since sales started in December. Retail investors can't support the spend right now.
Could AXIM/MJNA have their credit cards cut in half before Verséa is able to roll this out to the whole country? If that happens, Verséa might be forced to buy the assets at fire-sale prices. However AXIM/MJNA have a controlling share of the company. Is that where AXIM is right now? I don't know.
Let's see what happens in the next few weeks.
Looks like some longs are already exiting...
Why is Verséa Health creating a stock corporation in the state of California?
Does this mean anything to AXIM and MJNA?
Versea Health, Inc., a Stock Corporation, is a business entity located in Tampa, FL. Officially filed on April 4, 2024, this corporation is recognized under the document number 6173732. Governed by the California Secretary of State, the corporation maintains an active filing status. Last Updated 5/8/2024 8:12:42 PM
I have no idea what any of this means. Link to website:
https://www.bizprofile.net/fl/tampa/versea-health-inc
A stock corporation governed by the state of California. Officially filed April 4th. Statement of information filed on April 19th. Document Number 6173732 was last updated 5/8/2024 8:12:42 PM
I found another website to search for corporations. I just searched on Verséa.
Verséa and Verséa Ophthalmics and other Verséa divisions are listed numerous times for multiple states.
https://opencorporates.com/companies
Don't know what it all means, but lots of activity in April and May 2024.
The entry from California is dated April 4th, 2024 and the details from the website in previous post are the following:
BTW, I'm going to search on the filing number 6173732 to see what turns up. Do we have something happening behind the scenes that will soon be reported in a press release???
VERSEA HEALTH, INC. is a California Stock Corporation - Out Of State - Stock filed on April 4, 2024. The company's filing status is listed as Active and its File Number is 6173732.
The Registered Agent on file for this company is Corporation Service Company Which Will Do Business IN California As Csc - Lawyers Incorporating Serv and is located at 2710 Gateway Oaks Drive Ste 150n, Sacramento, CA 95833. The company's principal address is 603 East Cass Street, Tampa, FL 33602 and its mailing address is 603 East Cass Street, Tampa, FL 33602.
The company has 3 contacts on record. The contacts are Jillian Berswick from Tampa FL, Robert Glashow from Tampa FL, and Sean Fetcho from Tampa FL.
Hey Blue, Another question here. What is the California website that keeps track of corporations there in California? Any information you can provide is appreciated.
Thanks.
This Bizapedia website seems to say that Sean Fetcho is associated with corporations in Florida. New York and California.
https://www.bizapedia.com/people/sean-fetcho.html
"These individuals collectively are associated with 11 companies in Clearwater FL, New York NY, Sacramento CA, Tallahassee FL, and Tampa FL."
I'm just trying to dig and find out what might be unique about Verséa and how that might relate to California and New York.
Medical Coverage vs Vision Coverage.
https://reviewob.com/3-steps-we-took-in-our-practice-to-sharply-reduce-reliance-on-managed-vision-care-plans/
This doctor points out that Red Eye (and Dry Eye) procedures are billed through a patients medical coverage and not their Managed Vision Care.
"When patients come to you with a red eye, they understand when you tell them their appointment will be billed to medical. There is usually minimal resistance. Additionally, this is a great place to “train” your patients on the value you provide to them for care beyond glasses and contact lenses."
The AXIM Diagnostics tests are a totally new revenue stream for some of these Eye doctor offices. Billed through medical insurance instead of Vision Care.
Dr Janelle Davidson of Marietta Georgia announced she is opening her practice. She replied to Kyke Klute's post that she just completed her CLIA Lab Director courses and is adding #TPOC diagnostic tests.
Her office is a New Customer somewhere in the pipeline. In my opinion Q2 sales should tell us a lot about AXIM's revenue growth expectations.
https://www.linkedin.com/posts/dr-janelle-davison-028aa824_visionarydryeyeinstitute-dryeyerelief-grandopening-ugcPost-7193243599470239744-3ugB?utm_source=share&utm_medium=member_android
Not investment advice.
Verséa is listed as manufacturer in this article from a few days ago. The authors appear to teach at Ophthalmology medical schools in Miami and Toronto.
https://www.ophthalmologymanagement.com/issues/2024/may/dry-eye-diagnostics-in-real-time-practice/
At least the tests are getting name recognition.
A Third thing I noticed about this post is that Jessica Barr is not mentioned. This new customer called out "Thank you" to Kerry Robbers and Rahim Hirji. I believe Rahim Hirji has past work experience and his current title of "VP Marketing, Clinical Training and Implementation" would imply that he is qualified to "Approve" that a new customer has met the CLIA standards and requirements and can start selling the new AXIM Diagnostics tests.
If this turns out to be true, then we may see more than one new customer added per week. If Rahim Hirji becomes the second person on the Verséa Ophthalmics staff that is allowed to approve a CLIA compliance certification then time to cashflow positive for AXIM is cut in half.
THREE Takeaways from this post by a new customer:
In my opinion a case can be made that there is a significant backlog of new customers in the process of becomming CLIA Compliant. This eye doctor appears to have taken the steps to become CLIA compliant.
Now we know that Eye Doctors can take an online self-paced course to become CLIA compliant as a Lab Director.
And the third thing we learned from this post is that Jessica Barr might have some help from VP Rahim Hirji to certify a new customer.
Good luck to all.
Not investment advice.
Reread this post and the replies to this post. A second AXIM/Verséa customer replied to the post and mentioned she just completed the Lab Director Certification.
There are self-paced Lab Director courses available online. Here is a link.
https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments/training
Quote:
"The courses listed below are designed to meet the Clinical Laboratory Improvement Amendments (CLIA) requirement at 42 CFR 493.1405(b)(2)(ii)(B)."
This certification might be a requirement before Verséa Ophthalmics sends a person to verify CLIA compliance.
RE: Btw, I have not seen an "official announcement" about this customer from the Verséa Ophthalmics LinkedIn page.
This is the basis of my opinion about significant backlogs within the sale channel.
From the July 2023 AXIM Press Release about manufacturing and shipping Diagnostics tests and the five months of silence until the December 20th 2023 Press Release about manufacturing partner Auer Precision I believe there was a growing backlog of sales demand that was not getting filled.
After the Auer Precision announcement or around the same time, we started seeing the #TPOCTITAN announcements on the Verséa Ophthalmics LinkedIn page. About one announcement a week since the first one.
This new customer has not been officially announced yet. Are they "CLIA Certified". I think I have seen a prior post that they are CLIA Certified. But they have not been announced as a #TPOCTITAN.
There may be significant backlogs at every stage of the new customer sales channel.
Just my opinion.
Not investment advice.
LinkedIn post by a new customer.
https://www.linkedin.com/posts/kyledkluteod_optometrists-dryeye-eyecare-activity-7193277260458594304-UOAG?utm_source=share&utm_medium=member_android
Btw, I have not seen an "official announcement" about this customer from the Verséa Ophthalmics LinkedIn page.
ARVO-2024
Verséa Health (Verséa Ophthalmics) has booth MS6 at ARVO 2024 in Seattle May 5-9.
It sure seems like something changed at the beginning of April. Not just the corporate address but the lack of communication on the LinkedIn Verséa Ophthalmics page. I subscribe to the ARVO posts on LinkedIn. Noticed today the 2024 ARVO meeting in Seattle and searched their website for Verséa.
Found them on the Exhibitors list here:
https://events.ntpshow.com/ARVO2024/Public/exhibitors.aspx
They are obviously going to the meeting.
They have a booth at the meeting.
Posts on LinkedIn seem to be Free.
So far no announcement from Verséa about being at ARVO 2024. Maybe they are just too busy to post updates??
Meeting website
https://www.arvo.org/annual-meeting/
I can't believe this is holding a penny. The longer it takes for this company to show results the more it looks like a scam...just my 2 cents
Btw, I do believe there is a backlog of customers waiting for the approval that they are CLIA compliant and can begin selling. One of those eye doctor offices posted on LinkedIn a few weeks ago. I have not yet seen the announcement they are approved and selling the AXIM tests.
In my opinion we will continue to see at least 1 new customer every week until CLIA Waiver Applications have been submitted and approved.
It feels too slow but customers do like how the AXIM test system can help their customers and businesses.
If there truly is a backlog of customers waiting for CLIA compliance training, then my guess is Verséa Ophthalmics will prioritize adding more resources that can help Eye doctor offices get setup and trained as CLIA compliant locations.
There are companies and individuals that provide contract services to help with CLIA compliance training and setup. Hiring more people for that role may not be necessary if CLIA Waivers are submitted and approved sooner rather than later.
Jessica Barr may have the "train the trainers" experience on her resume as well.
At current pace AXIM has gained an average of one new customer per week over the last 4.5 months. The number of existing customers selling AXIM tests may be close to 20 locations at this time. At some point AXIM will provide some sales numbers that can be validated against original expectations.
Until AXIM is cashflow positive someone on the inside is financing the difference to gain an ever larger share of the business.
Good luck to all.
Not investment advice.
Slowly but surely building a solid customer base .. thank you for the update Tex
New customer from Edmond Oklahoma.
BVA Better Vision Ahead.
Appears to be half a dozen eye doctors and just as many locations in that area.
https://www.linkedin.com/posts/vers%C3%A9a-ophthalmics_tpoctitans-tpoc-osd-activity-7191406107049771009-USgZ?utm_source=share&utm_medium=member_android
BVA Website
https://bva20-20.com/
Hashtags related to AXIM Biotech and business partners.
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
After having a few days to look at the sunbiz.org information about Verséa my impression is that not much has changed.
First the parent company changed their name from Verséa Holdings to Verséa Health.
Second all of the corporate entities changed their address. Current address is about a mile away from previous address.
Third while each division is separated into their own corporate subsidiaries it seems they share resources and are fully owned by the parent company.
Last. Maybe it is not that big a deal to be setup as a Foreign Limited Liability Company? I don't know . I'm not sure what the benefits are.
Just a quick list and 100% opinion.
I was trying not to say the name last night. ;o)
The Verséa companies and the Dr Sambursky connection seem much better skilled dealing with the FDA. Let's hope that continues especially as it relates to the AXIM products.
I stopped speaking of Empowered Dynamics on this board because someone posted evidence that they were dead. I have continued to believe that we would be seeing Rick and Barry in a later scene in the movie. The chance of him losing his own funds on an EUA play appears to be fairly slim. He has been around too long to bankroll a long shot.
What I noticed last night was that Brett Parent has a foundational role with Verséa but looking at LinkedIn he has also had a foundational role in a number of companies associated with Rick Hennessey. So there is a common thread that loosely ties together Verséa and AXIM and Empowered Diagnostics.
I do think having an ISO-13485 certified manufacturer in Auer Precision is much more stable than building a manufacturing company from scratch.
The other Versea divisions are not registered separately. The exist as part of Versea Health.
Time for me to shut down for the night. Sunbiz.org is filled with information.
Then with a little help from LinkedIn.
All the dots seem to be connected to
Brett Parent.
Past and present.
Interesting.
Somehow things are going to work out for AXIM this time.
Thanks for the tip about
Sunbiz.org
I wonder what this means?
What foreign country is first?
When?
Detail by Entity Name
Foreign Profit Corporation
VERSEA OPHTHALMICS, INC.
Filing Information
Document Number. F24000001901
FEI/EIN Number. 88-4015030
Date Filed: 04/05/2024
State. DE
Status. ACTIVE
I believe Dr Sambursky helped Lumos Diagnostics setup a corporate base in Australia.
I'm not sure how many countries they sold products into.
It is good to know that Verséa Ophthalmics has a goal to sell internationally. It seems like the Verséa parent company is growing rapidly. Let's hope the Ophthalmics division grows rapidly as well.
I've been watching Sunbiz and the proliferation of filings by the various components of Versea including the foreign opthalmics subsidiary that is incorporated in Delaware. There is some fancy footwork being exhibited in the dance.
Did anyone else get an email from Verséa a couple of days ago about the change in address?
While searching the new business address I found something very interesting. Use the link below. I have no idea what this means with the relationship with AXIM. Maybe nothing.
Company Age 21 days
"Versea Diagnostics, LLC is a business entity based in Tampa, FL. Established recently on April 5, 2024, this Foreign Limited Liability Company is recognized under the document number M24000004463."
https://www.bizprofile.net/fl/tampa/versea-diagnostics-llc
Cut/Paste of the email below.
Dear Valued Customers and Partners,
We are excited to share that Verséa Health has moved to a new location as part of our ongoing growth and commitment to delivering exceptional service. This move will help us optimize our business operations and enhance our ability to serve you better.
Effective TODAY, our new office address is:
603 E Cass Street, Tampa, FL 33602
Please note that our phone numbers and email addresses remain the same.
Here's what this move means for you:
Shipping and Deliveries: Please update your records with our new address for all future shipments and deliveries to avoid any disruptions.
Billing and Invoices: Kindly ensure that all billing documents and invoices issued after April 24, 2024, reflect our new address.
Communication: We are here to assist you through this transition. If you have any questions or concerns, please feel free to contact us via our usual phone numbers and email addresses.
We are dedicated to making this move as seamless as possible and are working diligently to minimize any potential disruptions to our ongoing projects and collaborations.
Thank you for your continued support and understanding during this exciting time.
We look forward to continuing our valued partnership from our new location and are thrilled about the opportunities this move will bring for all of us!
Best regards,
Sean Fetcho
Founder & CEO
Verséa Health, Inc.
Every one of these articles has links to other articles. This is another one from a year ago.
https://www.statnews.com/2023/04/12/parkinsons-biomarkers-michael-j-fox-foundation/
Tear Biomarkers in Alzheimer's and Parkinson's Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review)
I just read the abstract summary of this study, but other diseases can be diagnosed through tear drops.
https://pubmed.ncbi.nlm.nih.gov/36077520/
Remember back to the video interview of CEO Mr Huemoeller by Benzinga? I think Mr Huemoeller mentioned Alzheimers.
https://finance.yahoo.com/news/video-axim-biotechnologies-ceo-presents-130000171.html
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, CA, March 27, 2024...
Six minute video embedded in this article from May 2022. Mark Lew MD discusses why tears can be used for testing for Parkinson Disease.
https://www.neurologylive.com/view/motivations-for-using-tears-confirm-parkinson-disease-diagnosis-mark-lew
Interesting video.
AXIM Press release from September 2023
From Yahoo
https://finance.yahoo.com/news/axim-biotechnologies-develops-first-non-130000370.html
SAN DIEGO,, September 12, 2023--AXIM Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM Biotech," "AXIM" or "the Company"), an international healthcare diagnostic solu...
Same press release different source.
https://www.insideprecisionmedicine.com/topics/patient-care/tear-drop-test-is-first-rapid-point-of-care-diagnostic-for-parkinsons-disease/
Michael J Fox foundation reported one year ago in April 13, 2023 about the new biomarker.
The AXIM press release about the new TPOC test for Parkinson Disease was in September 2023 just 6 months after the initial discovery.
In my opinion the TPOC Tear-based Parkinson Disease Point-of-Care test is a really big deal. Hope we hear more news about this test soon.
https://www.michaeljfox.org/news/breaking-news-parkinsons-disease-biomarker-found
TPOC Parkinson Disease test. Tear-based Point-of-Care test. This article is a month old but great summary about the new test developed by AXIM scientists.
https://www.darkdaily.com/?p=46757
Not investment advice.
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
#Biovance #Biovance3L
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Blue Skys - Do you think AXIM’s 1st Quarter 2024 revenue will be substantially more than the couple of thousand they’ve brought in thus far with all of the offices they’ve signed up for TPOC? Thanks so much
Maybe people are starting to believe this company is a scam? I know I'm halfway there...but still watching and will jump in of I see a good reason.
Ugh, what is happening to the stock today?
Official announcement of a new customer has been shared from the Verséa Ophthalmics LinkedIn page. The Pearle Vision is from Ohio.
https://www.linkedin.com/posts/vers%C3%A9a-ophthalmics_tpoctitans-tpoc-optometry-activity-7188507259646156801-odNR?utm_source=share&utm_medium=member_android
According to the Verséa Ophthalmics April 3rd press release this Pearle Vision is one of 68 that signed an exclusive agreement with Verséa Ophthalmics for their #Biovance and #Biovance3L products.
https://www.versea.com/west-point-optical-group-llc-and-versea-ophthalmics-inc-announce-partnership-supply-agreement-for-biovanceand-biovance-3l-ocular/
too bad have some still selling low.
Big volume yesterday. Something must be up. Or maybe a Doctor who really likes the tests?
Another detail I wanted to share from the 10K.
PAGE 14.
"On February 20, 2024, AXIM announced that Verséa™ Ophthalmics, LLC, placed an order for an additional 50 of IUL Lateral Flow Readers."
ONLY 50 READERS????
I realize $2000 per reader adds up quickly.
50 × $2000 = $100,000.
BUT
If AXIM and Verséa were anywhere close to CLIA Waiver approval, they would not order just 50 readers. If CLIA Waiver is anywhere close to approval there would be an order of 300 or 500 or 1000 readers.
Besides that, according to one post or video some customers are purchasing two readers so they can run both tests concurrently to save time.
Look at AXIM realistically.
This company has a lot of potential and hopefully just a few months down the road.
Keep watching.
Hang on to some dry powder.
About the only things to budge AXIM share price in the short-term is a potential merger or acquisition or a new merchandising agreement for the Parkinsons disease test. I do think AXIM has to consider a merchandising agreement for the Parkinsons disease test because they are bleeding too much cash right now.
New customer posted to the Verséa Ophthalmics LinkedIn account.
https://www.linkedin.com/posts/vers%C3%A9a-ophthalmics_welcome-to-dry-eye-center-of-west-virginia-activity-7186431660182097920-_b6D?utm_source=share&utm_medium=member_android
QuickVue® Adenoviral Conjunctivitis Test by Quidel is also listed for sale on the Verséa Ophthalmics website.
Verséa Ophthalmics is building their business.
The AXIM tests are a focal point but not the only line of revenue.
Why has Verséa Ophthalmics been so quiet on LinkedIn recently?
I have to believe the TPOC Tear-based Parkinson Disease Point-of-Care test is a really big deal for Verséa to have exclusive merchandising rights to. In my opinion the marketing agreement for the Parkinson Disease test can bring upfront cash and also revenue $ per test sold.
My guess is the Parkinson Disease test would not be limited to eyecare locations.
Thanks. I figured that the AS was in there somewhere. How could there be a derivative liability for insufficient shares with the new AS?
The copy/paste makes me nervous...zero progress. There is enough going on to where this isn't a scam company like MJNA. However, inability to produce results will yield the same result...crash of share price
Followers
|
105
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5280
|
Created
|
04/29/14
|
Type
|
Free
|
Moderators Blue Skys Squirrel Hunter |
Unlike currently available serological COVID-19 tests that detect an antibody response to the virus, AXIM’s rapid 10-minute test measures a specific subpopulation of antibodies to block binding of the virus to host cell receptors. While there are expensive, time consuming laboratory tests that measure neutralizing antibodies, NeuCovixTM differs in that it is a portable, low cost, rapid point-of-care test with results in 10 minutes.
“We are hopeful our test fills an important need in these uncertain times. While other tests merely show whether someone was infected with coronavirus, we took it a step further by creating a test that stratifies individuals into those who have neutralizing antibodies, which are essential in preventing reinfection, and those who don’t. The test can be deployed for point of care use in convalescent plasma transfusions to severely ill patients and for evaluating efficacy of upcoming vaccines in generating protective antibodies,” said Sergei Svarovsky, PhD, MBA, AXIM’s CSO and co-inventor of NeuCovixTM.
An immediate application of NeuCovixTM, a point-of-care test, is to measure levels of neutralizing antibodies in convalescent plasma so that plasma with the highest levels of neutralizing antibodies can be identified and administered to patients fighting COVID-19. Without this knowledge, many patients could be undertreated with non-neutralizing plasma and may not benefit from this treatment.
Another application of NeuCovixTM is to help ensure that vaccines elicit high levels of neutralizing antibodies. When a vaccine is available, manufacturers can employ the NeuCovixTM rapid, point-of-care test to evaluate protective immune responses in vaccine recipients.
AXIM® Biotech CEO John W. Huemoeller II commented, “Our goal was to make this test, accurate, fast and relatively inexpensive so it could serve as an ‘Immunity Passport port™’ for vaccine developers around the world as they begin larger Phase II and III clinical trials. We are optimistic that NeuCovixTM will be widely used, becoming the gold standard in assessing levels of immunity.”
Doug Lake, Ph.D. and co-inventor of NeuCovixTM commented, “Everybody who recovers from COVID-19 makes antibodies against the virus, but since all antibodies are not created equal, you really want to know if the antibodies you make neutralize the virus. People who recover want to make sure they are protected from re-infection and that they won’t infect others.”
AXIM also announced the filing of a pre-Emergency Use Authorization Application (EUA) and has already initiated dialogue with the FDA in order to finalize its EUA submission. The intellectual property relating to the novel serological test is the subject of Provisional Patent Application No. 63/023,646 “Convalescent Plasma Testing and Treatment” filed on May 12, 2020.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The Company is also developing novel antibodies for therapeutic and diagnostic uses for oncological therapeutics. For more information, please visit www.AXIMBiotech.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |